Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsDividends Paid - CommonFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fortress Biotech (FBIO) Share-based Compensation: 2009-2024

Historic Share-based Compensation for Fortress Biotech (FBIO) over the last 16 years, with Dec 2024 value amounting to $32.6 million.

  • Fortress Biotech's Share-based Compensation fell 51.36% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $42.5 million, marking a year-over-year increase of 110.95%. This contributed to the annual value of $32.6 million for FY2024, which is 91.55% up from last year.
  • Per Fortress Biotech's latest filing, its Share-based Compensation stood at $32.6 million for FY2024, which was up 91.55% from $17.0 million recorded in FY2023.
  • Over the past 5 years, Fortress Biotech's Share-based Compensation peaked at $32.6 million during FY2024, and registered a low of $13.5 million during FY2020.
  • Over the past 3 years, Fortress Biotech's median Share-based Compensation value was $23.0 million (recorded in 2022), while the average stood at $24.2 million.
  • In the last 5 years, Fortress Biotech's Share-based Compensation decreased by 25.92% in 2023 and then surged by 91.55% in 2024.
  • Over the past 5 years, Fortress Biotech's Share-based Compensation (Yearly) stood at $13.5 million in 2020, then skyrocketed by 44.87% to $19.5 million in 2021, then rose by 17.97% to $23.0 million in 2022, then fell by 25.92% to $17.0 million in 2023, then skyrocketed by 91.55% to $32.6 million in 2024.